Trial Profile
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Anidulafungin; Caspofungin; Fluconazole; Micafungin; Voriconazole
- Indications Candidaemia; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms MARIO
- Sponsors SCYNEXIS
- 16 Nov 2023 According to a Scynexis media release ,status changed from recruiting to suspended.
- 13 Nov 2023 According to a Scynexis media release , clinical hold is placed on the MARIO trial this quarter.
- 02 Nov 2023 This trial has been suspended in Bulgaria.